US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

CervoMed

9.80

+0.31003.27%

Post-market: 10.000.2000+2.04%19:59 EDT

Volume:337.53K

Turnover:3.38M

Market Cap:85.29M

PE:-4.86

High:10.40

Open:9.77

Low:9.60

Close:9.49

Loading ...

Overview Company News Filings

CervoMed’s Promising Data and Phase 3 Prospects Boost Buy Rating

CervoMed Reports Positive Phase 2b Trial Results

Calendar of U.S. Earnings Expected in the Week Ahead

Calendar of U.S. Earnings Expected in the Week Ahead

CervoMed to present results on Phase 2b RewinD-LB study

Investigators to Present Clinical Trial Results Showing Neflamapimod Slows Clinical Progression in Dementia with Lewy Bodies in Oral Presentation at AD/PD™ 2025

CervoMed Is Maintained at Buy by D. Boral Capital

CervoMed Announces Oral Presentation at 19TH International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurologic Disorders (AP/Pd™)

THOMSON REUTERS

CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurologic Disorders (AP/PD™)

CervoMed Is Maintained at Buy by Roth MKM

CervoMed Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.

Cervomed Inc. Faces Financial Hurdles Due to Regulatory Restrictions on Public Float

CervoMed Shares Rise After Positive Data From Neflamapimod Trial

CervoMed Is Maintained at Buy by D. Boral Capital

CervoMed FY 2024 GAAP EPS $(2.02) Misses $(1.81) Estimate, Sales $9.738M Beat $9.537M Estimate

CervoMed Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Updates

Capital One, CervoMed, HPE, Eaton, PepsiCo: Trending by Analysts

BUZZ-CervoMed up after Jones Research upgrades rating

CervoMed upgraded to Buy at JonesResearch on more confidence in DLB program

CervoMed Inc : Jonestrading Raises to Buy From Hold

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CRVO/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CRVO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CRVO\",,,,,undefined,":{"symbol":"CRVO","market":"US","secType":"STK","nameCN":"CervoMed","latestPrice":9.8,"timestamp":1744920000000,"preClose":9.49,"halted":0,"volume":337533,"hourTrading":{"tag":"盘后","latestPrice":10,"preClose":9.8,"latestTime":"19:59 EDT","volume":10764,"amount":109858.11,"timestamp":1744934385765},"delay":0,"floatShares":5797499,"shares":8702719,"eps":-2.017884,"marketStatus":"Closed Good Friday","change":0.31,"latestTime":"04-17 16:00:00 EDT","open":9.77,"high":10.4,"low":9.6,"amount":3380017.658304,"amplitude":0.084299,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.017884,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":9.49,"preHourTrading":{"tag":"盘前","latestPrice":9.69,"preClose":9.49,"latestTime":"09:28 EDT","volume":2983,"amount":28843.8037935,"timestamp":1744896494698},"postHourTrading":{"tag":"盘后","latestPrice":10,"preClose":9.8,"latestTime":"19:59 EDT","volume":10764,"amount":109858.11,"timestamp":1744934385765},"volumeRatio":0.5386974879740317},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CRVO\",,,,,undefined,":{"symbol":"CRVO","floatShares":5797499,"roa":"-42.94%","roe":"-69.95%","lyrEps":-2.017884,"volumeRatio":0.5386974879740317,"shares":8702719,"dividePrice":0,"high":10.4,"amplitude":0.084299,"preClose":9.49,"low":9.6,"week52Low":1.8,"pbRate":"2.18","psRate":"8.76","week52High":25.69,"institutionHeld":0,"latestPrice":9.8,"eps":-2.017884,"divideRate":0,"volume":337533,"delay":0,"ttmEps":-2.017884,"open":9.77,"prevYearClose":2.34,"prevWeekClose":8.495,"prevMonthClose":9.15,"prevQuarterClose":9.15,"fiveDayClose":8.47,"twentyDayClose":11.56,"sixtyDayClose":2.18},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CRVO\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2526457366","title":"CervoMed’s Promising Data and Phase 3 Prospects Boost Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2526457366","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526457366?lang=en_us&edition=fundamental","pubTime":"2025-04-12 04:15","pubTimestamp":1744402516,"startTime":"0","endTime":"0","summary":"Soumit Roy, an analyst from JonesTrading, maintained the Buy rating on CervoMed (CRVO – Research Report). The associated price target remains the s...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/cervomeds-promising-data-and-phase-3-prospects-boost-buy-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/cervomeds-promising-data-and-phase-3-prospects-boost-buy-rating?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRVO"],"gpt_icon":0},{"id":"2525787079","title":"CervoMed Reports Positive Phase 2b Trial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2525787079","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525787079?lang=en_us&edition=fundamental","pubTime":"2025-04-08 04:30","pubTimestamp":1744057839,"startTime":"0","endTime":"0","summary":"CervoMed ( ($CRVO) ) has provided an update. On April 2, 2025, CervoMed announced positive clinical results from the first sixteen weeks of the ope...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cervomed-reports-positive-phase-2b-trial-results-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cervomed-reports-positive-phase-2b-trial-results-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRVO","BK4139"],"gpt_icon":0},{"id":"2525090470","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2525090470","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525090470?lang=en_us&edition=fundamental","pubTime":"2025-04-07 18:00","pubTimestamp":1744020000,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Dave & Buster's Ent                             4Q       .67       AMC. ·Kura Sushi USA                                  2Q      (.11)  4:05 PM. ·RPM Intl Inc.                                    3Q       .50   6:45 AM. ·Delta Air Lines Inc.                             1Q       .44   6:30 AM. ·Simply Gd Foods                                 2Q       .40   7:00 AM. ·Byrna Tech Inc.                                 1Q       .05   8:00 AM. ·Bank of N Y Mellon                                1Q      1.51   6:30 AM. ·Wells Fargo & Co                                 1Q      1.23   7:00 AM","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KRUS","NRIX","BLK","LU0795875169.SGD","LU2242649171.HKD","LU0052756011.USD","LU0128525689.USD","SMPL","BK","LU0980610538.SGD","LU2106854487.HKD","BK4113","MAMA","LU0320765489.SGD","LU1201861249.SGD","PGR","KMX","BK4500","BSVN","LU0787776722.HKD","FAST","NEOG","CRVO","BK4212","STZ","BYRN","LU2264538146.SGD","TBBB","LU1551013425.SGD","CALM","LU0238689110.USD","LU2552382058.USD","IE00BN8TJ469.HKD","CARM","RPM","LU0098860793.USD","DAL","LU1481011671.HKD","AMC","UNTY","PSMT","WAFD","IE00B1XK9C88.USD","LU2361044865.SGD","LEVI","TLRY","LAKE","LU1064131342.USD","LOVE","PLAY"],"gpt_icon":0},{"id":"2524239365","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2524239365","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524239365?lang=en_us&edition=fundamental","pubTime":"2025-04-03 18:00","pubTimestamp":1743674400,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·MSC Indus Dir.                                   2Q       .68   6:30 AM. ·Dave & Buster's Ent                             4Q       .69       AMC. ·Kura Sushi USA                                  2Q      (.10)  4:05 PM. ·RPM Intl Inc.                                    3Q       .51   6:45 AM. ·Delta Air Lines Inc.                             1Q       .44   6:30 AM. ·Simply Gd Foods                                 2Q       .40   7:00 AM","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4152","DAL","KRUS","BK4585","LNN","LU2552382132.HKD","BK4568","LU0310800965.SGD","APOG","BK4559","MAMA","CAG","CARM","PLAY","CALM","LAKE","BK4557","BK4155","AYI","BK4096","BK4139","BK4504","BK4086","RDUS","PSMT","AMC","RPM","LEVI","LU0128525689.USD","LU0203347892.USD","NEOG","IE00B66KJ199.SGD","BK4113","TLRY","BK4167","BK4202","LU0203345920.USD","LU0052756011.USD","TBBB","SLP","LU1267930227.SGD","LU0757428866.USD","STZ","MSM","CRVO","LW","NRIX","BK4212","SMPL","LU1815336091.USD"],"gpt_icon":0},{"id":"2524461584","title":"CervoMed to present results on Phase 2b RewinD-LB study","url":"https://stock-news.laohu8.com/highlight/detail?id=2524461584","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524461584?lang=en_us&edition=fundamental","pubTime":"2025-04-02 19:10","pubTimestamp":1743592246,"startTime":"0","endTime":"0","summary":"CervoMed (CRVO) announced that investigators plan to present results, including new results, from the Extension phase of the Phase 2b RewinD-LB stu...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cervomed-to-present-results-on-phase-2b-rewind-lb-study-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cervomed-to-present-results-on-phase-2b-rewind-lb-study-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LB","BK4139","CRVO","BK4233","BK4213"],"gpt_icon":0},{"id":"2524940495","title":"Investigators to Present Clinical Trial Results Showing Neflamapimod Slows Clinical Progression in Dementia with Lewy Bodies in Oral Presentation at AD/PD™ 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2524940495","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524940495?lang=en_us&edition=fundamental","pubTime":"2025-04-02 19:00","pubTimestamp":1743591600,"startTime":"0","endTime":"0","summary":"During the first 16 weeks of the Extension phase of the RewinD-LB clinical study neflamapimod slowed clinical progression compared to controls, as assessed by Clinical Dementia Rating Sum of Boxes  and Clinical Global Impression of Change . Neflamapimod was associated with a reduced incidence of falls in the Extension phase of the study and new data to be presented at AD/PD 2025 demonstrates improvements on endpoints measuring cognitive fluctuations and working memory. “The presentation of the Extension phase data at AD/PD 2025 is an opportunity to share our findings and engage deeply with the DLB medical community as we plan for pivotal development and work to bring neflamapimod to patients as rapidly as possible,” said John Alam, MD, Co-Principal Investigator of the RewinD-LB study and CEO of CervoMed. “The positive findings across the primary outcome measure and multiple additional clinically important endpoints evaluated in the first 16 weeks of the Extension phase strengthen our b","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/investigators-present-clinical-trial-results-110000131.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1169589451.USD","LU0345774391.USD","TUG","LU0345774631.USD","LU0348723411.USD","BK4097","LU0205194284.USD","CGIC","DLB","LU0240877869.USD","BK4139","BK4023","LU0205193047.USD","PD","LU1169590202.USD","LU0240878834.USD","CRVO"],"gpt_icon":0},{"id":"2522765948","title":"CervoMed Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2522765948","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522765948?lang=en_us&edition=fundamental","pubTime":"2025-03-26 19:35","pubTimestamp":1742988900,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CRVO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 26, 2025 07:35 ET (11:35 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO"],"gpt_icon":0},{"id":"2522022552","title":"CervoMed Announces Oral Presentation at 19TH International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurologic Disorders (AP/Pd™)","url":"https://stock-news.laohu8.com/highlight/detail?id=2522022552","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522022552?lang=en_us&edition=fundamental","pubTime":"2025-03-25 20:00","pubTimestamp":1742904005,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nTUA7RRM5C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CRVO"],"gpt_icon":0},{"id":"2522243022","title":"CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurologic Disorders (AP/PD™)","url":"https://stock-news.laohu8.com/highlight/detail?id=2522243022","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522243022?lang=en_us&edition=fundamental","pubTime":"2025-03-25 20:00","pubTimestamp":1742904000,"startTime":"0","endTime":"0","summary":"BOSTON, March  25, 2025  (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced it will deliv","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/25/3048644/0/en/CervoMed-Announces-Oral-Presentation-at-19th-International-Conference-on-Alzheimer-s-and-Parkinson-s-Diseases-and-Related-Neurologic-Disorders-AP-PD.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DLB","PD","LU1169589451.USD","LU0240878834.USD","BK4139","LU0240877869.USD","LU0205193047.USD","LU0345774391.USD","LU0345774631.USD","BK4023","LU1169590202.USD","LU0348723411.USD","BK4097","CRVO","LU0205194284.USD"],"gpt_icon":0},{"id":"2520606218","title":"CervoMed Is Maintained at Buy by Roth MKM","url":"https://stock-news.laohu8.com/highlight/detail?id=2520606218","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520606218?lang=en_us&edition=fundamental","pubTime":"2025-03-18 22:36","pubTimestamp":1742308560,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CRVO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 18, 2025 10:36 ET (14:36 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":"9bc4bc206e695fae65d16887a7636aa7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO"],"gpt_icon":0},{"id":"2520624326","title":"CervoMed Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags","url":"https://stock-news.laohu8.com/highlight/detail?id=2520624326","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520624326?lang=en_us&edition=fundamental","pubTime":"2025-03-18 18:41","pubTimestamp":1742294494,"startTime":"0","endTime":"0","summary":"NasdaqCM:CRVO Earnings and Revenue History March 18th 2025. All figures shown in the chart above are for the trailing 12 month  period. Revenue exceeded analyst estimates by 4.3%. Earnings per share  missed analyst estimates by 9.0%.Looking ahead, revenue is expected to decline by 1.9% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the US are expected to grow by 20%.The company's shares are up 308% from a week ago.We don't want to rain on the parade too much, but we did also find 5 warning signs for CervoMed (3 don't sit too well with us!) that you need to be mindful of.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cervomed-full-2024-earnings-revenues-104134424.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CRVO"],"gpt_icon":1},{"id":"2520982466","title":"Cervomed Inc. Faces Financial Hurdles Due to Regulatory Restrictions on Public Float","url":"https://stock-news.laohu8.com/highlight/detail?id=2520982466","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520982466?lang=en_us&edition=fundamental","pubTime":"2025-03-18 14:01","pubTimestamp":1742277701,"startTime":"0","endTime":"0","summary":"Cervomed Inc. (CRVO) has disclosed a new risk, in the Regulation category. Cervomed Inc. faces a significant financial risk due to certain regulato...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cervomed-inc-faces-financial-hurdles-due-to-regulatory-restrictions-on-public-float?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cervomed-inc-faces-financial-hurdles-due-to-regulatory-restrictions-on-public-float?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CRVO"],"gpt_icon":0},{"id":"2520570140","title":"CervoMed Shares Rise After Positive Data From Neflamapimod Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2520570140","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520570140?lang=en_us&edition=fundamental","pubTime":"2025-03-18 00:59","pubTimestamp":1742230740,"startTime":"0","endTime":"0","summary":"CervoMed shares were up 28% to $8.27 after the company said it saw positive results from a Phase 2b trial for neflamapimod.The clinical-stage company on Monday said that, following \"highly encouraging\" 16-week extension results from the Phase 2b trial, it believes it has established proof-of-concept for neflamapimod as a potential treatment for dementia with Lewy bodies.The Boston-based company said it is now focusing on reporting the results from a 32-week extension phase in the second half of 2025, and on discussing next steps on Phase 3 trial design with regulatory authorities.Initial safety, biomarker and pharmacokinetic data from an ongoing trial in patients with a mild-to-moderate form of the disease, who are being treated with a twice-daily regimen of neflamapimod in the study, is expected to be available in the fourth quarter.CervoMed also said that as of Dec. 31 it had $38.9 million in cash, cash equivalents and marketable securities, compared with $7.8 million as of Dec. 31, ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO","BK4139"],"gpt_icon":1},{"id":"2520208925","title":"CervoMed Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2520208925","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520208925?lang=en_us&edition=fundamental","pubTime":"2025-03-17 22:04","pubTimestamp":1742220240,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CRVO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 17, 2025 10:04 ET (14:04 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":"016d41f4580f6dca87db8a5e96195d68","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO"],"gpt_icon":0},{"id":"2520540913","title":"CervoMed FY 2024 GAAP EPS $(2.02) Misses $(1.81) Estimate, Sales $9.738M Beat $9.537M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2520540913","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520540913?lang=en_us&edition=fundamental","pubTime":"2025-03-17 20:06","pubTimestamp":1742213174,"startTime":"0","endTime":"0","summary":"CervoMed (NASDAQ:CRVO) reported quarterly losses of $(2.02) per share which missed the analyst consensus estimate of $(1.81) by 11.6 percent. The company reported quarterly sales of $9.738 million which beat the analyst","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44354096/cervomed-fy-2024-gaap-eps-2-02-misses-1-81-estimate-sales-9-738m-beat-9-537m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"CervoMed FY 2024 GAAP EPS $(2.02) Misses $(1.81) Estimate, Sales $9.738M Beat $9.537M Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO"],"gpt_icon":0},{"id":"2520540669","title":"CervoMed Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2520540669","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520540669?lang=en_us&edition=fundamental","pubTime":"2025-03-17 20:00","pubTimestamp":1742212800,"startTime":"0","endTime":"0","summary":"-Reported positive 16-week results from the extension phase of the Phase 2b RewinD-LB trial of neflamapimod in dementia with Lewy bodies (DLB), including improvement on the trial’s primary outcome mea","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/17/3043647/0/en/CervoMed-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results-and-Provides-Corporate-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0348723411.USD","LU0345774631.USD","BK4097","LU0205193047.USD","LU0240878834.USD","CRVO","DLB","LU0240877869.USD","LU0205194284.USD","LU0345774391.USD"],"gpt_icon":1},{"id":"2519397245","title":"Capital One, CervoMed, HPE, Eaton, PepsiCo: Trending by Analysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2519397245","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519397245?lang=en_us&edition=fundamental","pubTime":"2025-03-15 17:01","pubTimestamp":1742029306,"startTime":"0","endTime":"0","summary":"Analysts are intrested in these 5 stocks: ( ($COF) ), ( ($CRVO) ), ( ($HPE) ), ( ($ETN) ) and ( ($PEP) ). Here is a breakdown of their recent","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/weekend-updates/capital-one-cervomed-hpe-eaton-pepsico-trending-by-analysts?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/weekend-updates/capital-one-cervomed-hpe-eaton-pepsico-trending-by-analysts?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["COF","PEP","CRVO","HPE"],"gpt_icon":0},{"id":"2519856723","title":"BUZZ-CervoMed up after Jones Research upgrades rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2519856723","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519856723?lang=en_us&edition=fundamental","pubTime":"2025-03-13 23:48","pubTimestamp":1741880910,"startTime":"0","endTime":"0","summary":"BUZZ-CervoMed up after Jones Research upgrades rating** Shares of drug developer CervoMed CRVO.O rise 4.4% to $6.44** Brokerage Jones Research upgrades CRVO to \"buy\" rating from \"hold\", keeps PT of $15** Upgrade follows CRVO's announcement of positive results from study of its drug, neflamapimod, in patients with dementia with Lewy bodies  on Monday** Data from study is boosting investor confidence, and we are seeing a more riskon approach heading into the next steps for netlamapimod in DLB patients - Jones Research ** DLB is a form of dementia caused by the accumulation of protein deposits called Lewy bodies in the brain's nerve cells** Up to Wednesday's close, stock up 176.7% YTD  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250313:nL4N3PW1A9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO"],"gpt_icon":0},{"id":"2519485987","title":"CervoMed upgraded to Buy at JonesResearch on more confidence in DLB program","url":"https://stock-news.laohu8.com/highlight/detail?id=2519485987","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519485987?lang=en_us&edition=fundamental","pubTime":"2025-03-13 23:25","pubTimestamp":1741879536,"startTime":"0","endTime":"0","summary":"JonesResearch upgraded CervoMed (CRVO) to Buy from Hold with a $15 price target arguing that the company’s latest data from the open label extensio...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cervomed-upgraded-to-buy-at-jonesresearch-on-more-confidence-in-dlb-program?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cervomed-upgraded-to-buy-at-jonesresearch-on-more-confidence-in-dlb-program?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRVO","DLB"],"gpt_icon":0},{"id":"2519855676","title":"CervoMed Inc : Jonestrading Raises to Buy From Hold","url":"https://stock-news.laohu8.com/highlight/detail?id=2519855676","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519855676?lang=en_us&edition=fundamental","pubTime":"2025-03-13 23:18","pubTimestamp":1741879134,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250313:nFWN3PW19H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CRVO"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":1,"totalSize":111,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CRVO\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-17","symbol":"CRVO","fiscalQuarterEnding":"2024/12","expectedEps":-0.67,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1742184000000,"reportTimeType":"pre","actualEps":-0.8},{"market":"US","date":"2024-11-12","symbol":"CRVO","fiscalQuarterEnding":"2024/09","expectedEps":-0.41,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-0.55},{"date":"2024-08-12","symbol":"CRVO","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2024/06","expectedEps":-0.24,"defaultRemindTime":1723449600000,"name":null,"time":"Pre-Market","dateTimestamp":1723435200000,"actualEps":-0.27},{"date":"2024-05-15","symbol":"CRVO","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1715760000000,"name":null,"time":"Pre-Market","dateTimestamp":1715745600000,"actualEps":null},{"date":"2024-04-01","symbol":"CRVO","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2023/12","expectedEps":-0.95,"defaultRemindTime":1711958400000,"name":null,"time":"Pre-Market","dateTimestamp":1711944000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CRVO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CRVO\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0.8571,"hold":0.1429,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.8571,"analysts":7,"updateTime":1741924800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CRVO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CRVO","date":"2025-04-17","current":-5.069692,"percent":0.75969,"low":-119.682483,"twenty":-41.877374,"median":-24.063652,"eighty":-4.723843,"high":-1.31262,"avg":-28.425455,"sd":26.680301,"marketCap":82588803},"quantilePoints":[{"date":"2023-09-01","current":-5.788607,"twenty":-5.849231,"median":-5.813052,"eighty":-5.769051,"marketCap":33591560},{"date":"2023-09-08","current":-5.135433,"twenty":-5.817941,"median":-5.700604,"eighty":-4.975855,"marketCap":29801161},{"date":"2023-09-15","current":-4.791246,"twenty":-5.769051,"median":-5.182368,"eighty":-4.935961,"marketCap":27803825},{"date":"2023-09-22","current":-4.51746,"twenty":-5.708427,"median":-5.1589,"eighty":-4.822536,"marketCap":26215035},{"date":"2023-09-29","current":-4.66902,"twenty":-5.505043,"median":-5.045475,"eighty":-4.536234,"marketCap":27094543},{"date":"2023-10-06","current":-5.250814,"twenty":-5.262548,"median":-5.040586,"eighty":-4.536234,"marketCap":30470722},{"date":"2023-10-13","current":-6.893527,"twenty":-5.817941,"median":-5.065031,"eighty":-4.595684,"marketCap":40003462},{"date":"2023-10-20","current":-8.995809,"twenty":-6.690143,"median":-5.197035,"eighty":-4.691783,"marketCap":52203100},{"date":"2023-10-27","current":-9.201148,"twenty":-7.153624,"median":-5.22148,"eighty":-4.714546,"marketCap":53394692},{"date":"2023-11-03","current":-8.379791,"twenty":-8.309389,"median":-5.27037,"eighty":-4.77036,"marketCap":48628322},{"date":"2023-11-10","current":-9.709606,"twenty":-8.530373,"median":-5.764162,"eighty":-4.78929,"marketCap":56345302},{"date":"2023-11-17","current":-41.851906,"twenty":-9.287195,"median":-5.866832,"eighty":-4.791246,"marketCap":55950767},{"date":"2023-11-24","current":-43.761983,"twenty":-9.977525,"median":-6.385068,"eighty":-4.83818,"marketCap":58504301},{"date":"2023-12-01","current":-41.597229,"twenty":-22.855354,"median":-7.177091,"eighty":-4.969206,"marketCap":55610296},{"date":"2023-12-08","current":-37.39506,"twenty":-39.737313,"median":-7.68555,"eighty":-5.041564,"marketCap":49992521},{"date":"2023-12-15","current":-37.352614,"twenty":-39.16082,"median":-8.389569,"eighty":-5.054275,"marketCap":49935776},{"date":"2023-12-22","current":-28.736045,"twenty":-38.685423,"median":-8.477572,"eighty":-5.063075,"marketCap":38416500},{"date":"2023-12-29","current":-26.825968,"twenty":-38.401034,"median":-8.868694,"eighty":-5.079111,"marketCap":35862966},{"date":"2024-01-05","current":-39.899383,"twenty":-38.549596,"median":-9.044699,"eighty":-5.121353,"marketCap":53340488},{"date":"2024-01-12","current":-39.88198,"twenty":-39.488419,"median":-9.670494,"eighty":-5.172981,"marketCap":53317222},{"date":"2024-01-19","current":-38.625999,"twenty":-39.313626,"median":-10.04206,"eighty":-5.199968,"marketCap":51638132},{"date":"2024-01-26","current":-38.965567,"twenty":-39.313626,"median":-10.775414,"eighty":-5.223436,"marketCap":52092093},{"date":"2024-02-02","current":-34.593614,"twenty":-39.237223,"median":-27.727949,"eighty":-5.242992,"marketCap":46247338},{"date":"2024-02-09","current":-43.719537,"twenty":-39.237223,"median":-28.736045,"eighty":-5.262548,"marketCap":58447556},{"date":"2024-02-16","current":-68.677874,"twenty":-39.888941,"median":-31.961952,"eighty":-5.505043,"marketCap":91813733},{"date":"2024-02-23","current":-59.169936,"twenty":-40.466999,"median":-34.275268,"eighty":-5.692782,"marketCap":79102808},{"date":"2024-03-01","current":-63.372175,"twenty":-41.597229,"median":-35.401364,"eighty":-5.759273,"marketCap":84720676},{"date":"2024-03-08","current":-73.849585,"twenty":-41.945287,"median":-36.142899,"eighty":-5.808163,"marketCap":98727664},{"date":"2024-03-15","current":-76.245081,"twenty":-43.210183,"median":-36.501144,"eighty":-5.849231,"marketCap":101930142},{"date":"2024-03-22","current":-103.758666,"twenty":-50.901256,"median":-37.320992,"eighty":-6.027192,"marketCap":138712367},{"date":"2024-03-28","current":-90.558053,"twenty":-57.709789,"median":-37.373837,"eighty":-6.291199,"marketCap":121064797},{"date":"2024-04-05","current":-61.481111,"twenty":-59.566286,"median":-37.479952,"eighty":-6.48676,"marketCap":133529165},{"date":"2024-04-12","current":-71.595379,"twenty":-59.997513,"median":-38.212361,"eighty":-6.942417,"marketCap":155496070},{"date":"2024-04-19","current":-71.737433,"twenty":-62.930842,"median":-38.413768,"eighty":-7.153624,"marketCap":155804594},{"date":"2024-04-26","current":-94.969175,"twenty":-65.856384,"median":-38.647222,"eighty":-7.237715,"marketCap":206260987},{"date":"2024-05-03","current":-91.738931,"twenty":-67.584491,"median":-38.965567,"eighty":-7.396119,"marketCap":199245307},{"date":"2024-05-10","current":-90.826862,"twenty":-70.379394,"median":-39.220244,"eighty":-7.806798,"marketCap":197264409},{"date":"2024-05-17","current":-48.426621,"twenty":-71.185147,"median":-39.390029,"eighty":-8.309389,"marketCap":201061130},{"date":"2024-05-24","current":-37.632017,"twenty":-70.941929,"median":-39.252477,"eighty":-8.383702,"marketCap":156243317},{"date":"2024-05-31","current":-39.142864,"twenty":-70.600999,"median":-39.231253,"eighty":-8.399347,"marketCap":162516160},{"date":"2024-06-07","current":-38.288042,"twenty":-69.492975,"median":-39.142864,"eighty":-8.458016,"marketCap":158967051},{"date":"2024-06-14","current":-39.282021,"twenty":-68.840894,"median":-39.122984,"eighty":-8.473661,"marketCap":163093922},{"date":"2024-06-21","current":-42.542269,"twenty":-68.382795,"median":-39.092906,"eighty":-8.635976,"marketCap":176630057},{"date":"2024-06-28","current":-34.133213,"twenty":-68.186075,"median":-39.083225,"eighty":-8.741579,"marketCap":141716732},{"date":"2024-07-05","current":-31.54887,"twenty":-67.93606,"median":-38.965567,"eighty":-8.944963,"marketCap":130986869},{"date":"2024-07-12","current":-31.668147,"twenty":-66.717294,"median":-38.65716,"eighty":-9.034921,"marketCap":131482094},{"date":"2024-07-15","current":-31.707906,"twenty":-66.428229,"median":-38.645875,"eighty":-9.044699,"marketCap":131647168},{"date":"2024-08-02","current":-24.571142,"twenty":-66.410457,"median":-38.635937,"eighty":-9.075989,"marketCap":102016238},{"date":"2024-08-09","current":-22.543427,"twenty":-66.310958,"median":-38.456214,"eighty":-9.287195,"marketCap":93597422},{"date":"2024-08-16","current":-27.887378,"twenty":-66.13481,"median":-38.31907,"eighty":-9.647027,"marketCap":140643746},{"date":"2024-08-23","current":-25.694357,"twenty":-65.856384,"median":-38.201961,"eighty":-9.711562,"marketCap":129583733},{"date":"2024-08-30","current":-27.036355,"twenty":-65.492725,"median":-38.049488,"eighty":-9.848454,"marketCap":136351801},{"date":"2024-09-06","current":-24.27053,"twenty":-64.492663,"median":-37.878225,"eighty":-10.364736,"marketCap":122402979},{"date":"2024-09-13","current":-27.789183,"twenty":-63.372175,"median":-37.791053,"eighty":-10.687412,"marketCap":140148522},{"date":"2024-09-20","current":-28.591109,"twenty":-62.958476,"median":-37.555984,"eighty":-10.775414,"marketCap":144192855},{"date":"2024-09-27","current":-25.056089,"twenty":-62.820306,"median":-37.39506,"eighty":-10.956308,"marketCap":126364774},{"date":"2024-10-04","current":-21.291948,"twenty":-61.546921,"median":-37.320992,"eighty":-18.460659,"marketCap":107381170},{"date":"2024-10-11","current":-20.65368,"twenty":-61.481111,"median":-37.075389,"eighty":-19.851755,"marketCap":104162211},{"date":"2024-10-18","current":-22.993995,"twenty":-60.002788,"median":-36.396302,"eighty":-20.65368,"marketCap":115965061},{"date":"2024-10-25","current":-20.571851,"twenty":-59.976413,"median":-36.164122,"eighty":-20.2609,"marketCap":103749524},{"date":"2024-10-31","current":-23.043092,"twenty":-59.793721,"median":-35.612321,"eighty":-20.509661,"marketCap":116212673},{"date":"2024-11-08","current":-20.506388,"twenty":-59.656441,"median":-34.614837,"eighty":-20.378734,"marketCap":103419374},{"date":"2024-11-15","current":-7.544112,"twenty":-59.364528,"median":-34.033815,"eighty":-19.864847,"marketCap":90130851},{"date":"2024-11-22","current":-6.618369,"twenty":-59.195404,"median":-32.598152,"eighty":-10.920129,"marketCap":79070838},{"date":"2024-11-29","current":-7.461209,"twenty":-58.838839,"median":-31.688026,"eighty":-10.106595,"marketCap":89140402},{"date":"2024-12-06","current":-6.715088,"twenty":-58.392606,"median":-31.54887,"eighty":-9.138568,"marketCap":80226362},{"date":"2024-12-13","current":-1.333346,"twenty":-58.187646,"median":-30.753634,"eighty":-8.46975,"marketCap":15929720},{"date":"2024-12-20","current":-1.540602,"twenty":-56.826908,"median":-30.356096,"eighty":-8.266296,"marketCap":18405842},{"date":"2024-12-27","current":-1.658046,"twenty":-55.349782,"median":-29.88401,"eighty":-7.711877,"marketCap":19808978},{"date":"2025-01-03","current":-1.540602,"twenty":-54.314096,"median":-29.245398,"eighty":-7.461209,"marketCap":18405842},{"date":"2025-01-10","current":-1.506059,"twenty":-53.736829,"median":-28.656572,"eighty":-7.247045,"marketCap":17993155},{"date":"2025-01-17","current":-1.457699,"twenty":-49.142285,"median":-28.610519,"eighty":-7.137979,"marketCap":17415393},{"date":"2025-01-24","current":-1.568236,"twenty":-48.569754,"median":-27.928293,"eighty":-6.857839,"marketCap":18735992},{"date":"2025-01-31","current":-1.554419,"twenty":-47.997222,"median":-27.789183,"eighty":-6.629423,"marketCap":18570917},{"date":"2025-02-07","current":-1.540602,"twenty":-46.896292,"median":-27.420952,"eighty":-6.014862,"marketCap":18405842},{"date":"2025-02-14","current":-1.512967,"twenty":-44.339166,"median":-26.825968,"eighty":-5.724072,"marketCap":18075692},{"date":"2025-02-21","current":-1.606232,"twenty":-43.761983,"median":-26.659941,"eighty":-5.262548,"marketCap":19189947},{"date":"2025-02-28","current":-1.506059,"twenty":-43.736515,"median":-26.497871,"eighty":-5.163594,"marketCap":17993155},{"date":"2025-03-07","current":-1.485333,"twenty":-43.013176,"median":-26.414453,"eighty":-5.041564,"marketCap":17745543},{"date":"2025-03-14","current":-4.000037,"twenty":-42.484599,"median":-25.784369,"eighty":-4.787335,"marketCap":47789160},{"date":"2025-03-21","current":-6.175515,"twenty":-42.267878,"median":-25.530698,"eighty":-4.787335,"marketCap":100603431},{"date":"2025-03-28","current":-4.54082,"twenty":-42.072626,"median":-25.219748,"eighty":-4.727048,"marketCap":73973111},{"date":"2025-04-04","current":-6.004566,"twenty":-41.996223,"median":-24.761504,"eighty":-4.759999,"marketCap":97818561},{"date":"2025-04-11","current":-4.524793,"twenty":-41.928309,"median":-24.40964,"eighty":-4.724538,"marketCap":73712029},{"date":"2025-04-17","current":-5.069692,"twenty":-41.877374,"median":-24.063652,"eighty":-4.723843,"marketCap":82588803}],"updateTime":1745006584275}}}